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Abstract
The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and
ESRP2) control the epithelial-to-mesenchymal transition (EMT)
splicing program in cancer. However, their role in breast cancer
recurrence is unclear. In this study, we report that high levels of
ESRP1, but not ESRP2, are associated with poor prognosis in
estrogen receptor positive (ER+) breast tumors. Knockdown of
ESRP1 in endocrine-resistant breast cancer models decreases
growth significantly and alters the EMT splicing signature, which
we confirm using TCGA SpliceSeq data of ER+ BRCA tumors.
However, these changes are not accompanied by the development
of a mesenchymal phenotype or a change in key EMT-transcrip-
tion factors. In tamoxifen-resistant cells, knockdown of ESRP1
affects lipid metabolism and oxidoreductase processes, resulting
in the decreased expression of fatty acid synthase (FASN),
stearoyl-CoA desaturase 1 (SCD1), and phosphoglycerate dehydro-
genase (PHGDH) at both the mRNA and protein levels. Further-
more, ESRP1 knockdown increases the basal respiration and spare
respiration capacity. This study reports a novel role for ESRP1
that could form the basis for the prevention of tamoxifen resis-
tance in ER+ breast cancer.
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Introduction
The estrogen receptor positive (ER+) subtype constitutes approxi-
mately 70% of all breast cancers. Despite the success of endocrine
therapies in the early stage of ER+ breast cancer, at least 20% of
patients will suffer a distant recurrence within 10 years [1,2]. More
specifically, the intrinsic or acquired resistance to endocrine therapy
limits its utility in these patients, leading to recurrence. Thus, it is
crucial to identify the underlying molecular mechanisms of recur-
rence/resistance to improve the success of endocrine therapies and
prevent breast cancer mortality.
Several studies have sought to understand the basis of recurrence
by studying tamoxifen/endocrine therapy resistance models [3–5].
Acquired resistance models, such as the stepwise increase in treat-
ment with tamoxifen or fulvestrant in vitro, estrogen deprivation or
the overexpression of a marker that confers endocrine resistance,
have been used in vitro and in vivo to study this phenomenon.
Crosstalk between ER and other signaling pathways and epigenetic
mechanisms are well-documented mechanisms of recurrence/resis-
tance in endocrine resistance. Using Next-Gen sequencing, the
importance of ER mutations in endocrine resistance has been
demonstrated [6–8]. Other studies have evaluated the resistance
mechanisms using ER+ tumors from patients treated before surgery
and reported that FGFR1 amplification confers antiestrogen resis-
tance to ER+ breast cancer and that the ERa pathway remains active
in estrogen-deprived ER+/FGFR1-amplified breast cancers [9].
Changes in biological processes such as proliferation and oxidative
phosphorylation have also been reported to contribute to tamoxifen
resistance [10].
Aberrant alternative splicing in cancer, including breast cancer,
is an emerging field and may affect genes and proteins both at the
expression and functional levels. These events are regulated by
complex processes involving the core spliceosome machinery and
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multiple regulatory factors [11]. Mutations in splicing factors or
changes in expression levels of the proteins may contribute to aber-
rant alternative splicing. The splicing factor 3b subunit 1, SF3B1,
was one of the mutated genes identified using next-generation
sequencing of breast tumors [12–14]. We have previously demon-
strated the upregulation of SF3B1 and SF3B3, another SF3B subunit,
in acquired endocrine-resistant models as well as in cases with
Oncotype Dx high recurrence scores [15]. However, only SF3B3
expression is correlated with a poor prognosis in the patients with
ER+ breast cancer [15].
A number of splicing factors have been reported to affect the
hallmarks of cancer [16]. Epithelial splicing regulatory proteins
(ESRPs—ESRP1 and ESRP2) are implicated in invasion, metastasis,
and the regulation of the splicing program involved in the epithelial-
to-mesenchymal transition (EMT) in cancer [17–19]. ESRP1
promotes lung cancer metastasis by regulating CD44 splicing in ER-
negative 4T1 mouse mammary tumor cells [20]. The relevance of
ESRPs to breast cancer is not clear. In this study, we sought to deter-
mine the role of ESRPs in ER+ breast cancer and have identified a
novel aspect of ESRP1 functionality in endocrine therapy-resistant
breast cancer.
Results
High ESRP1 expression correlates with worse prognosis in ER+
breast cancer
To determine the clinical relevance of ESRP1 and ESRP2 in breast
cancer, we first correlated the gene expression levels with the over-
all survival (OS) using the BreastMark tool, which integrates the
gene expression and survival data from 26 datasets based on 12 dif-
ferent microarray platforms [21]. This analysis showed that a higher
expression of ESRP1 correlated with a worse prognosis for ER+
breast cancer [Hazard ratio (HR) = 2.01 (1.53–2.64); Score (log
rank) test = 26.4 on 1 df, P = 2.8 e-07 (n = 934, number of
events = 216)] (Fig 1A) using Cox proportional hazards regression
analysis. However, ESRP1 expression was not prognostic in patients
with estrogen receptor negative (ER) breast cancers (Fig 1B;
HR = 1.15 (0.8–1.68); Score (log rank) test = 0.58 on 1 df,
P = 0.4481; n = 322, number of events = 130). Expression of ESRP2
was not associated with the overall survival of patients with ER+
tumors [Fig EV1A; HR = 1.117 (0.82–1.51); Score (log rank)
test = 0.53 on 1 df, P = 0.47 (n = 708, number of events = 171)] as
well as the overall survival of patients with ER-negative tumors
[Fig EV1B; HR = 1.37 (0.91–2.04); Score (log rank) test = 2.31 on 1
df, P = 0.13 (n = 253, number of events = 96)] in BreastMark
datasets.
We further assessed the correlation of ESRP1 expression with the
overall survival in tamoxifen-treated patients using the same plat-
form in the BreastMark database. A high expression of ESRP1 was
associated with a shorter overall survival in the patients with ER+
tumors that were treated with tamoxifen [Fig 1C; HR = 5.021
(2.434–10.36); Score (log rank) test = 23.55 on 1 df, P = 1.218 e-06
(n = 210, number of events = 49)]. On the other hand, the overall
survival was independent of ESRP1 expression in the patients
treated with chemotherapy alone (Fig 1D; HR = 1.599 (0.6773–
3.773); Score (log rank) test = 1.17 on 1 df, P = 0.28 (n = 129,
number of events = 21)). The effect of ESRP1 levels in the patients
treated with a combination of tamoxifen and chemotherapy was not
significant (data not shown), probably due to the small numbers in
the cohort.
Analysis of the Cancer Genome Atlas Breast Invasive Carcinoma
(TCGA-BRCA) [12] cohort also revealed that high ESRP1 expression
was associated with a significantly shorter overall survival in ER+
breast cancer patients [Fig 1E; P = 0.00011 (n = 656, number of
events = 62)], but not in ER cases [Fig 1F; P = 0.19 (n = 100,
number of events = 17)]. The limitation of the TCGA dataset was
that the treatment status was not available for all cases. The expres-
sion of ESRP2 was not associated with the overall survival in either
the ER+ or ER datasets using the TCGA cohorts (Fig EV1C and D).
Collectively, these results show that ESRP1 expression (but not
ESRP2) is prognostically important in the ER+ subtype of breast
cancer.
The association of high ESRP1 expression with poor prognosis in
ER+ breast cancer was further confirmed by quantitative RT-qPCR
in a cohort of patients with a high Oncotype Dx recurrence score
(HS) (P = 0.01034) (Fig EV1E). Oncotype Dx is a commercial assay
developed using the National Surgical Adjuvant Breast and Bowel
Project (NSABP) B14 and B20 clinical trials that assess the recur-
rence of ER+ breast cancers [22]. A high recurrence score usually
predicts resistance to endocrine therapies.
To investigate the role of ESRP1 in ER+ preclinical models with
poor prognosis, we next determined ESRP1 expression at the mRNA
and protein levels in acquired tamoxifen-resistant LCC2 cells and
fulvestrant-resistant (and cross-resistant to tamoxifen) LCC9 cells
compared to therapy-sensitive parental MCF-7-AZ control cells
(Fig EV2A). ESRP1 levels were significantly higher in the LCC2 cells
(P = 0.0001) and LCC9 cells (P = 0.0001) than in the parental MCF-
7-AZ cells in both the mRNA (Fig EV2A) and protein analyses
(Fig EV2B). In addition, another poor prognostic ER+ cell line
(T-47D) displayed high ESRP1 levels at both levels (P = 0.0001).
Together, these results support the hypothesis that ESRP1 plays an
important role in recurrent and endocrine therapy-resistant ER+
breast cancer.
Knockdown of ESRP1 in ER+ breast cancer impacts cell and
tumor growth in endocrine-resistant breast cancer
To further understand the functional role of ESRP1 in recurrence/
resistance to endocrine therapy, we first established stable ESRP1
knockdown in the LCC2 (tamoxifen-resistant) and LCC9 (fulves-
trant-resistant) cell lines using a lentiviral shRNA approach. The
knockdown resulted in a dramatic decrease in both the mRNA and
protein levels in these cell lines (ESRP1 knockdown in LCC2 cells-
clone 2C1 and clone 2C3 cells, P < 0.05; ESRP1 knockdown in
LCC9 cells-clones 9C2, P = 0.0001 and clone 9C3 cells, P = 0.0021;
Fig 2A and B) compared to their control counterparts (LCC2 empty
vector-2-control and LCC9 empty vector-9-control). The clones with
the highest knockdown (2C3 for LCC2; 9C2 for LCC9) were chosen
to perform the functional and mechanistic studies. Knockdown was
also performed in T-47D cells, which have a higher level of ESRP1
compared to that of MCF-7 cells. Overexpression of ESRP1 has been
performed in MCF-7 cells, which have lower levels of endogenous
ESRP1. Appendix Fig S1A and B show the mRNA and protein
expression levels for both models.
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Figure 1. High ESRP1 expression correlates with poor prognosis in estrogen receptor positive (ER+) but not in estrogen receptor negative (ER) breast cancer.
A BreastMark microarray platform; Kaplan–Meier curves of overall survival (OS), demonstrating that high expression of ESRP1 (red line) is associated with poor
prognosis in ER+ breast cancer. A log rank test was used to calculate P = 2.8 e-07 (n = 934, number of events = 216).
B BreastMark microarray platform; Kaplan–Meier curves of overall survival (OS) of ER breast cancer. A log rank test was used to calculate P = 0.4481 (n = 322,
number of events = 130).
C BreastMark microarray platform; correlation of ESRP1 expression with overall survival in tamoxifen-treated patients. A log rank test was used to calculate P = 1.218,
e-06 (n = 210, number of events = 49).
D BreastMark microarray platform; correlation of ESRP1 expression with overall survival in chemotherapy-treated patients. A log rank test was used to calculate the
P = 0.28 (n = 129, number of events = 21)
E The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) RNA-Seq dataset; Kaplan–Meier curves of overall survival (OS) in ER+ breast cancer, demonstrating
that high expression of ESRP1 (red line) is associated with poor prognosis in ER+ breast cancer. A log rank test was used to calculate P = 0.00011 (n = 656, number of
events = 62).
F The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) RNA-Seq dataset; Kaplan–Meier curves of overall survival (OS) in ER breast cancer. Red-high
ESRP1 expression; Black-low ESRP1 expression. A log rank test was used to calculate P = 0.19 (n = 100, number of events = 17).
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To further analyze the impact of endocrine therapy on the ESRP1
knockdown cells, we determined the relative cell density in the pres-
ence and absence of b-estradiol (E2), tamoxifen (TAM), and fulves-
trant (ICI 182,780). These studies showed that ESRP1 knockdown in
LCC2 alone resulted in a significant (P < 0.0001) reduction in the
cell growth with a further decrease in the response to E2 and TAM
or the combination of these two agents (Fig 2C). Similar results
were observed in the LCC9 knockdown cells in response to fulves-
trant (P < 0.0001) but to a lesser degree compared to those treated
with tamoxifen (P < 0.01) (Fig 2C).
A significant reduction in the colony formation and cell growth
was observed in soft agar at 8 days in both the knockdown models
(Fig 2D). Despite the effect of ESRP1 knockdown on cell growth, no
changes were observed in the cell cycle or apoptosis in vitro
(Appendix Fig S2A and B). In vivo, knockdown of ESRP1 signifi-
cantly suppressed the tumor growth in the mammary fat pad of
orthotopic xenograft mice models of LCC2 and LCC9 (P < 0.05)
(Fig 2E), confirming the role of ESRP1 in cell growth and prolifera-
tion in endocrine therapy-resistant ER+ models.
ESRP1 knockdown does not induce an EMT phenotype in ER+
breast cancer
Lack of ESRP1 is known to induce EMT in epithelial cells. To better
understand the impact of ESRP1 knockdown on EMT in ER+ breast
cancer, we first assessed the morphology of the cells in both models.
Knockdown of ESRP1 switched the cells to a more glandular (nor-
mal) pattern compared to that of the control cell lines. No
mesenchymal patterns were observed in either model of ESRP1
knockdown (Fig 3A and B). We further analyzed the key EMT-indu-
cing transcription factors (EMT-TFs) and proteins associated with
the EMT process using Western blot analysis (Fig 3C). One of the
hallmarks of EMT is the loss of E-cadherin (encoded by CDH1) [23].
E-cadherin protein levels, representative of epithelialness, were not
significantly altered in both the ESRP1 knockdown cells (Fig 3C and
D). Vimentin was absent in these models. SLUG (SNAI2) and ZEB2
levels were down in the 2C3 cells but up in the 9C2 cells. SNAIL
(SNAI1) and ZEB1, both inducers of EMT and repressors of CDH1,
decreased in both the 2C3 and 9C2 knockdowns. Claudin-1 levels,
another regulator of EMT, remained unchanged in response to
ESRP1 knockdown. ZO-1 is not expressed in these models (data not
shown). We also confirmed these results in another cell line knock-
down model (T-47D-control and T-47D-kESRP1 knockdown) and in
an ESRP1 overexpression model (MCF-7-control and MCF-7-ESRP1)
(Fig 3E). These data show that the knockdown of ESRP1 does not
induce key EMT players in ER+ breast cancer models. In addition, a
change in in vitro invasive ability was not observed in either model
in response to knockdown (Appendix Fig S3). This suggests that
ESRP1’s key role in recurrence/resistance in ER+ breast cancer may
not be due to its impact on the EMT process.
Preca et al [24] reported that ZEB1 overexpression in MCF10A
downregulates ESRP1 and switches cells to CD44s, suggesting the
importance of ZEB1 for the EMT phenotype. In addition, ER+ and
luminal breast tumors mostly retain the CD44 variable exons [25].
High expression of CD44s has also been shown to be essential for
cells to undergo EMT [26]. To further understand the impact of
ESRP1 knockdown on the CD44 splice variants in our models, we
assessed the CD44s versus CD44v switch in response to ESRP1
knockdown using RT–qPCR (Appendix Fig S4). We observed that
the CD44s isoform is significantly dominant in the fulvestrant-resis-
tant knockdown (9C2) compared to CD44v2. However, this switch
from CD44v2 to CD44s was not significant in the 2C3-ESRP1 knock-
down (tamoxifen-resistant model). In 9C2-ESRP1 knockdown cells,
ZEB1 was not altered significantly compared to the levels in
9-control cells. In the 2C3 and 2-control cells, very low levels of
ZEB1 were present and were not induced in response to ESRP1
knockdown. These data clearly show that ESRP1’s role in our
models is different from that outlined by Preca et al and is indepen-
dent of EMT.
ESRP1 and epithelial splicing program
We next performed an Illumina paired-end RNA sequencing (RNA-
Seq) of the 2C3 and 9C2-ESRP1 shRNA knockdown cells and their
control counterparts (2-control and 9-control). This revealed signifi-
cant differences in the RNA profiles of these knockdown clones. The
differentially regulated genes were determined for each set alone
and the commonly overlapping sets based on a 2-fold change and
P < 0.05. Of the 1,178 significant genes, 484 were upregulated and
694 were downregulated in the 2C3 versus 2-control cells. In the
9C2 versus 9-control cells, 334 genes were significantly upregulated,
while 255 were downregulated.
▸Figure 2. Knockdown of ESRP1 decreases malignant and tumor growth significantly in endocrine-resistant ER+ breast cancer models.A RT–qPCR confirmed the stable knockdown of ESRP1 expression in endocrine-resistant cells using a shRNA lentiviral system (Mission TRC human shRNA constructs-
Sigma); 2-control (LCC2 cells transduced with pLKO.1 control vector) and 2C1 and 2C3 (LCC2 cells transduced with pLKO.1 shRNA ESRP1). Clones were selected for
expression verification (clone 1 and clone 3); 9-control (LCC9 cells transduced with pLKO.1 control vector), 9C2 and 9C3 (LCC9 cells transduced with pLKO.1 shRNA
ESRP1). Clones were selected for expression verification (clone 2 and clone 3). * represents P < 0.05; statistically significant. Data (mean  SD) were calculated using
two-way ANOVA based on three independent biological replicates.
B Western blot analysis using ESRP1 antibody GTX 131373 (GeneTex). GAPDH is used as the reference control.
C Relative cell density was determined by crystal violet assay. Cells were treated with TAM (4-hydroxytamoxifen; 106 M) or ICI (ICI 182,780; 109 M) for 6 days in the
presence and absence of E2 (b-estradiol; 1010 M). Data (mean  SD) were calculated using two-way ANOVA based on three independent biological replicates.
D Cell viability was determined using Cell Biolabs CytoSelectTM Cell Transformation Assay using 2-control, 2C3, 9-control, and 9C2 cells in CSM—charcoal-stripped
media, E2 (b-estradiol; 1010 M), and 10% fetal bovine serum. Data (mean  SD) were calculated using two-way ANOVA based on three independent biological
replicates.
E Impact of ESRP1 knockdown on in vivo tumor growth. Five million cells (2-control, 2C3, 9-control, and 9C2) were implanted into mammary fat pads of athymic mice
(five mice per group) in the presence of supplemental estrogen. Tumors were measured weekly using calipers for external measurements. Tumor volume was
calculated as L × W2/2, where L is length and W is width (note the different scale for tumor volumes). Data (mean  SD) were calculated using two-way ANOVA
(n = 5 mice per group).
Source data are available online for this figure.
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Figure 3. Knockdown of ESRP1 does not induce EMT in models of resistance to endocrine therapy.
A Cell morphology using high-power magnification (40x) of the cultured cell lines under a microscope in LCC2 model-2-control and 2C3 cells. Scale bar: 50 lm.
B Cell morphology using high-power magnification (40×) of the cultured cell lines under a microscope in LCC9 model-9-control and 9C2 cells. Scale bar: 50 lm.
C, D Protein expression of key EMT-TFs in ESRP1 knockdown cells (2C3 and 9C2) compared to endocrine-resistant control cell lines (2-control and 9-control) using
Western blotting analysis.
E Protein expression of key EMT-TFs in ESRP1 knockdown cells (T-47D-kESRP1) and ESRP1-overexpressing MCF-7 cells (MCF-7-ESRP1) compared to their control
counterparts (T-47D-control and MCF-7-control, respectively).
Source data are available online for this figure.
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Prior studies in epithelial cells, including ER-negative breast
cancer cells, have reported that ESRP1 regulates EMT by promoting
an epithelial splicing program [18,19,27]. To explore the effect of
knockdown on this program in ER+ breast cancer, we performed a
multivariate analysis of transcript splicing (MATS) analysis [28–30]
comparing the ESRP1 knockdown clones with corresponding control
cells using Illumina paired-end RNA-Seq (Fig 4A). In the 2C3 knock-
down versus 2-control cells, we identified 535 differential ASEs in
432 genes (P < 0.05 and Dw < 0.1; Fig 4A). The skipped exon (SE)
events comprised the largest group (348 SE (65%) in 289 genes
(66.9%)) and were followed by changes in 78 mutually exclusive
exons (MXE—14.6%) in 36 genes (8.3%), 40 retained introns (RI—
7.5%) in 40 genes (9.3%), 32 alternative 50 splice sites (A5SS—6%)
in 30 genes (6.9%), and 37 alternative 30 splice sites (A3SS—6.9%)
in 37 genes (8.6%). Similar data were obtained for the 9C2 knock-
down versus 9-control cells and resulted in the identification of
1,083 significant ASEs (Fig 4A). The 1,083 events (842 genes) were
categorized as follows: 625 SE (57.7%) in 528 genes (62.7%), 216
MXE (19.9%) in 87 genes (10.3%), 91 RI (8.4%) in 86 genes
(10.2%), 76 A5SS (7%) in 70 genes (8.3%), and 75 A3SS (6.9%) in
72 genes (8.4%).
We further analyzed the role of ESRP1 in alternative splicing by
classifying the differential ASEs based on the ESRP motifs to deter-
mine direct control of the event by ESRP1. The ESRP binding motifs
(Fig 4A) were obtained from Dittmar et al [31] and analyzed based
on the following assumption: The presence of the motif in the down-
stream region of an exon results in the inclusion of the exon, while
upstream or intraexonic locations lead to the exclusion of the exon.
Among the significant events in the 2C3 knockdown versus 2-
control cells, 102 events (91 genes) harbored the predicted ESRP1
motifs consisting of 62 SE (61%) in 55 genes (60%), 22 MXE (22%)
in 18 genes (20%), 9 RI (9%) in 9 genes (10%), 7 A3SS (7%) in 7
genes (8%), and 2 A5SS (2%) in 2 genes (2%). Of the 1,083 events
in the 9C2 knockdown versus 9-control cells, 241 (20.4%) in 221
genes (26.2%) had ESRP1 motifs consisting of 132 SE (54.8) in 124
genes (56.1%), 41 MXE (17%) in 32 genes (14.5%), 26 RI (10.8%)
in 26 genes (11.8%), 23 A5SS (9.5%) in 21 genes (9.5%), and 19
A3SS (7.9%) in 18 genes (8.1%).
Warzecha et al [19] previously described a 10-gene EMT splicing
signature. We next analyzed the RNA-Seq data to understand the
impact of ESRP1 knockdown on this signature in these models. At
the gene level, ESRP1 knockdown did not change the mRNA expres-
sion of these genes (Fig 4B and D). In contrast, the ASEs of EMT-
related exons in ARHGEF11 (SE), RALGPS2 (SE), SCRIB (SE), SLK
(SE), and FLNB (A5SS) were present in both the LCC2 and LCC9
knockdown models, as indicated by the change in the splice index
(Fig 4C and E). Furthermore, ENAH (SE) and MAGI1 (SE and A3SS)
were identified only in the LCC2 model. The other three ASEs
(FNIP1, ARFGAP2, and SLC37A2) were not significant in either of
the cells.
To validate the RNA-Seq analysis, we employed an alternative
platform (Human Transcriptome Array 2.0 (HTA 2.0), Applied
Biosystems/Thermo Fisher Scientific, Santa Clara, CA) that identi-
fies ASEs using 10 probes per exon and 4 probes per exon–exon
junction. This analysis using Transcriptome Analysis Console (TAC)
3.0 validated seven of the 10 EMT ASE patterns in both cell lines
(Fig 5). In addition, the patterns for FLNB were confirmed in LCC2,
but not in the LCC9 model.
EMT alternative splicing program in human ESRP1high
ER+ breast cancers
Cell line models can be poor representations of cancer cell behav-
ior in patients. To better understand the importance of splicing
events, we analyzed them in the TCGA Breast Invasive Carci-
noma (BRCA) dataset. TCGA SpliceSeq is a resource for the
investigation of cross-tumor and tumor-normal alterations in the
mRNA splicing patterns of TCGA RNA-Seq data [32]. The survival
and splicing patterns in the cases (100 each) with the highest and
lowest ESRP1 expression were analyzed. Accordingly, the exon
skipping (SE) events comprised the largest group (290 SE corre-
sponding 279 genes) shown in Fig 6A. This pattern was followed
by alternative first exon (173 AP corresponding 173 genes), alter-
native last exon (89 AT corresponding 89 genes), retained intron
(5 RI corresponding to 5 genes), alternative 50 donor (33 AD
corresponding to 33 genes), alternative 30 acceptor (28 AA corre-
sponding 28 genes), and mutually exclusive exon (5 ME corre-
sponding to 5 genes) events. In the ESRP1_TCGA SpliceSeq BRCA
analysis of the EMT signature, ASEs were also identified in five
of the 10 genes (ARHGEF11, ENAH, FNIP1, SCRIB, and SLK;
Fig 6B), indicating that the patterns of ASEs in the LCC2 and
LCC9 models are identical to those described in the EMT gene
signature (Table 1). These results validate that ESRP1 regulates
the EMT-splicing program in ER+ breast cancer. However, the
EMT-splicing program is not sufficient to induce an EMT pheno-
type in this breast cancer subtype.
Novel functional role of ESRP1 knockdown on endocrine-
resistant breast cancer: impact of ESRP1 on metabolic pathways
To further identify and validate the functional role of ESRP1 knock-
down on endocrine-resistant breast cancer, we next analyzed the
differentially expressed genes in the 2C3 and 9C2 knockdown
models using the HTA 2.0 platform. In LCC2 versus 2C3 ESRP1
knockdown, the expression of 1,186 genes (1,263 transcripts) was
significantly altered, while 413 genes (432 transcripts) were signifi-
cantly regulated in the LCC9 versus 9C2 ESRP1 knockdown with an
FDR < 0.1. Volcano plots representing the distribution of the fold
changes (2 > FC > 2, FDR < 0.1) of these genes are shown in
Fig 7A. Of these significant genes, 34 downregulated and 68 upregu-
lated (102 genes total) were shared by both the 2C3 and 9C2 ESRP1
knockdowns (Fig 7B). Using the DAVID Functional Annotation
Clustering Tool, we identified the biological processes that were
significantly altered in response to ESRP1 knockdown. The most
significant annotation clusters downregulated by ESRP1 knockdown
consisted of fatty acid metabolism/lipid metabolism (SCD, ACACA,
FASN, ACAT2, PLCH1, and HPGD) and oxidoreductase processes
(SCD, PHGDH, FASN, DHTKD1, and HPGD). Other clusters, such as
the Ubl conjugation pathway (NEDD4, FBXO27, UBE2S, and UBE2T)
and extracellular exosome cluster (genes including MUC1, TEX14,
CD44 NEDD4, and ACACA), remained significant. In contrast, glyco-
sylation processes (including B4GALT1, CRISP3, ATP1B1, PXDN,
and MPZL) and some cytokine activity (TNFRSF11B, GDF15, BMP7,
and TIMP1) were upregulated in ESRP1 knockdown cells versus
control resistant cells. Surprisingly, no major EMT- or invasion-
related genes were significantly altered at the gene level. Taken
together, we have demonstrated a novel functional impact of ESRP1
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Figure 4. A unique set of EMT genes are altered at the splicing level but not at the gene level.
A Donut charts for RNA-Seq analysis showing the differentially regulated alternative splicing events (ASEs) and their corresponding genes in ESRP1 knockdown cells
compared to control cells; SE: skipped exon, RI: retained intron, MXE: mutually exclusive exons, A5SS: alternative 50 splice site, and A3SS: alternative 30 splice site. The
“percent spliced in” (PSI or w) value was estimated. Differences in inclusion levels (Δw) between samples and their significance were calculated (P < 0.05 and
IDwI > 0.1). Circle 1: all ASEs; Circle 2: all genes corresponding to all ASEs; Circle 3: significant ASEs; Circle 4: significant genes corresponding to significantly altered
ASEs; Circle 5: significant ASEs with ESRP1 motifs; Circle 6: significant genes corresponding to significantly altered ASEs with ESRP1 motifs. ESRP binding motifs were
obtained from Dittmar et al [31] and analyzed based on the following assumption: The presence of the motif in the downstream region of an exon results in
inclusion of the exon, while upstream or intraexonic location leads to exclusion of the exon.
B Radar plot showing that the EMT gene signature was not altered at the gene level in the ESRP1 knockdown model (LCC2 set).
C Radar plot showing that the EMT gene signature was altered at the ASEs level (SE) in the ESRP1 knockdown model (LCC2 set).
D Radar plot showing that the EMT gene signature was not altered at the gene level in the ESRP1 knockdown model (LCC9 set).
E Radar plot showing that the EMT gene signature was altered at the ASEs level (SE) in the ESRP1 knockdown model (LCC9 set).
Source data are available online for this figure.
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on the regulation of tumor growth at the functional and molecular
levels independent of EMT.
We next compared the expression levels of key fatty acid meta-
bolism/lipid metabolism and oxidoreductase processes at the gene,
alternative splicing, and protein level. FASN, SCD, and PHGDH were
altered at the alternative splicing and protein levels in the ESRP1
knockdown cells (Table 2 and Appendix Figs S5 and S6). The same
exon inclusions based on the splicing index levels were significant
in both the tamoxifen- and fulvestrant-resistant models (see loca-
tions in Table 2). At the protein level, decreased expression of FASN
and SCD1 in knockdown cells was observed, particularly in the
tamoxifen-resistant (2C3 versus 2-control) model (Fig 7C). These
results may be specific to acquired tamoxifen-resistant cells, as
FASN and SCD1 protein levels remained the same in response to
ESRP1 knockdown in the T-47D breast cancer cell line
(Appendix Fig S1A). On the other hand, PHGDH levels decreased in
both MCF-7-derived tamoxifen- and fulvestrant-resistant cells as
well as in T-47D cells. The results from the overexpression of ESRP1
in the MCF-7 model suggested that this by itself may not be suffi-
cient to result in the altered expression of these metabolic genes.
To confirm the functional importance of ESRP1 in the regulation
of cellular metabolism, we performed further experiments that
Figure 5. Validation of the ASEs events of 10 EMT genes in response to ESRP1 knockdown using HTA 2.0 Splicing viewer (Transcriptome Analysis Console (TAC)
Software-Applied Biosystems/Thermo Fisher Scientific).
All Probe Selection Regions (PSRs) and Junctions are represented in the structural view with boxes that have the same size. An inclusion junction detects two neighboring
PSRs. The PSRs detected by an inclusion junction are linked and graphically represented as dotted lines. An exclusion junction detects PSRs that are apart from each other.
The PSRs detected by an exclusion junction are linked and graphically represented as dotted lines. Altered ASE for each corresponding gene has been highlighted as light blue
representing the altered PSR. Red color indicates the inclusion of an exon, whereas green color represents the skipping of an exon. The blue column indicates the alternative
splicing event at the listed location.
Source data are available online for this figure.
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analyzed the metabolic substrate flux in response to ESRP1 knock-
down in resistant cells. The methods used to assess the glycolysis
rate and the oxidation of major fuel substrates, glucose, glutamine,
and fatty acids have been previously described [33]. Using the XF
Extracellular Flux analyzer, we measured the two major energy-
producing pathways of cell-mitochondrial respiration through the
oxygen consumption rate (OCR) and the extracellular acidification
rate (ECAR), indicative of glycolysis, of the ESRP1 knockdown cells
compared to their control resistant cells in real time. These analyses
demonstrated that ESRP1 knockdown did not significantly alter the
glycolysis rate (ECAR) in either the tamoxifen-resistant or fulves-
trant-resistant models (Fig EV3A–D).
To compare the oxygen consumption rate (OCR) between the
control and ESRP1 knockdown cells, we measured baseline respira-
tion and spare respiration capacity, which is defined as the difference
between the basal and maximum respiration for energy production
through oxidative phosphorylation. ESRP1 knockdown significantly
increased the basal respiration and spare respiration capacity in the
tamoxifen-resistant cells (P < 0.0001, Mann–Whitney U-test) but not
in the fulvestrant-resistant cells (Fig EV3E). Furthermore, we
showed a significant decrease in glucose uptake in the ESRP1 knock-
down tamoxifen-resistant cells and T-47D ESRP1 knockdown cells
(P < 0.05 for both cell lines; Student’s t-test). We did not observe
any differences in the L-lactate levels (Appendix Fig S7A and B).
Taken together, these results suggest that ESRP1-mediated regu-
lation of metabolic pathways might be more important for tamox-
ifen resistance than fulvestrant resistance. Further analysis will
determine how ESRP1 controls the metabolic and OXPHOS path-
ways in tamoxifen resistance. Targeting these genes/pathways could
provide novel therapeutic approaches for the control of recurrence/
resistance to tamoxifen therapy in ER+ breast cancer.
Discussion
Accumulating evidence suggests the key role of splicing factors in
cancer, including breast cancer [16,34]. Splicing factors, RNA-
binding proteins that interact with specific RNA sequences or
Table 1. Alternative splicing events of the EMT 10-gene splicing signature using three different platforms in ER+ ESRP1 low and high states.
Gene
symbol
Exon location
Warzecha et al [19]
NCBI-36-hg18
Exon location
GRCh37
Type of
ASE in
Warzecha
et al in low
ESRP1
2C3 versus
2-control
9C2
versus
9-control
2C3
versus
2-control
9C2
versus
9-control
TCGA
SpliceSeq
(low versus
high ESRP1)
RNA-Seq HTA RNA-Seq
ARFGAP2 Chr11:47,150,836–
47,150,877
Chr11:47,194,261–
47,194,302
Skip NS NS Skip Skip NS
ARHGEF11 Chr1: 155,174,834–
155,174,929
Chr1;155,908,305–
156,908,210
Inc Inc Inc Inc Inc Inc
ENAH Chr1:223,759,316–
223,759,378
Chr1:225,692,755–
225,692,693
Skip Skip NS Skip NS Skip
FLNB Chr3:58,102,625–
58,102,696
Chr3:58,127,585–
58,127,656
Skip NS NS NS Skip NS
FNIP1 Chr5:131,074,170–
131,074,253
Chr5:131,046,354–
131,046,271
Skip NS NS NS NS Skip
MAGI1 Chr3:65,408,737–
65,408,772
Chr3:65,433,732–
65,433,697
Inc Skip NS Inc Inc NS
RALGPS2 Chr1:177,127,988–
177,128,065
Chr1:178,861,365–
178,861,442
Skip Skip Skip Skip Skip NS
SCRIB Chr8:144,961,710–
144,961,772
Chr8:144,889,784–
144,889,722
Inc Inc Inc Inc Inc Inc
SLC37A2 Chr11:124,461,310–
124,461,366
Chr11:124,956,100–
124,956,156
Skip NS NS NS NS NS
SLK Chr10:105,760,564–
105,760,656
Chr10:105,770,574–
105,770,666
Skip Skip Skip Skip Skip Skip
◀ Figure 6. TCGA SpliceSeq analysis using BRCA dataset in ESRP1high and ESRP1low tumors.A The data were analyzed by categorizing the splice events into seven types: exon skip (ES), alternative 50 donor (AD), alternative 30 acceptor (AA), retained intron (RI),
mutually exclusive exons (ME), alternative first exon (AP), and alternative last exon (AT). The analysis of splice events was performed using the following filter criteria:
Min Gene RPKM ≥ 2, |dPSI| ≥ 0.1, P ≤ 0.02, Min Group Obs % > 0.85; RPKM-reads per kilobase of transcript per million aligned reads; and |dPSI|-absolute changes in
percent splicing (dPSI, ΔΨ). The events are presented as differential expression of splice events between ESRP1low and ESRP1high cases.
B TCGA splice graphs for the EMT signature genes in ESRP1high versus ESRP1low tumors. A splice graph of the gene’s exons is shaded based on the expression level and
shows the selected splice event outlined in red.
Source data are available online for this figure.
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AB
C
Figure 7. Impact of ESRP1 knockdown on endocrine-resistant breast cancer.
A Volcano plots showing the distribution of significant gene expression changes using the HTA 2.0 platform.
B Differential gene expression analysis of ESRP1 knockdown compared to resistant control cells using HTA 2.0 platform; downregulated genes in ESRP1 knockdown (left
panel) and upregulated genes in ESRP1 knockdown (right panel) common in 2-control versus 2C3, and 9-control versus 9C2.
C Validation of the protein levels of FASN, SCD1, and PHGDH protein levels in ESRP1 knockdown versus control resistant cell lines using Western blot analysis. GAPDH
was used as the loading control. The data are representative of three individual biological replicates.
Source data are available online for this figure.
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motifs, may act as master regulators of gene expression and cellular
behavior. Deregulation of their expression affects gene expression
and alternative splicing of genes that contribute to breast cancer
development and progression. In this study, we demonstrate for the
first time that elevated levels of the splicing factor ESRP1 (epithelial
splicing regulatory protein 1) are associated with poor outcomes in
ER+ breast cancer using microarray-based BreastMark and RNA-
Seq-based TCGA datasets. These results are in contrast to a prior
report from Lu et al, [27] who analyzed all (subtypes) breast
cancers from the TCGA (n = 877). The larger number of cases in the
provisional TCGA and subtype-specific analysis could explain the
observed differences in breast cancer. This led us to analyze an
independent cohort of ER+ cancers with Oncotype Dx scores [22],
an established surrogate of chemo- and endocrine resistance in
breast cancer and a predictor for low and high recurrence cases.
The correlation of high ESRP1 expression with poor prognosis (high
recurrence score) was validated by RT–qPCR. Although ESRP2
(epithelial splicing regulatory protein 2), an associated protein with
ESRP1, was also elevated in high recurrence cases, its expression
did not correlate with outcomes in either the BreastMark or TCGA
datasets. This led us to the conclusion that ESRP1, but not ESRP2, is
an important player in the recurrence of ER+ breast cancer.
The biological relevance of ESRP1 in ER+ breast cancer was con-
firmed using ESRP1 knockdown in established resistant cell lines to
endocrine therapy, representing models of poor prognosis. This
analysis showed that the loss of ESRP1 in knockdown cells not only
decreased the colony formation in vitro but also decreased the
tumor growth in the xenograft models, highlighting the importance
of ESRP1 in controlling cancer growth. Low ESRP1 expression has
been associated with the development of EMT in ER-negative breast
cancer model (MDA-MB-231 cells) [17–19]. In our study, we did not
observe the development of a mesenchymal phenotype in response
to knockdown of ESRP1. In contrast, glandular differentiation (more
epithelial than parental cells) was maintained in the therapy-resis-
tant ER+ breast cancer cells. To confirm this rather surprising
finding, we assessed the classical EMT proteins and the key EMT-
TFs in knockdown cells. Protein level data confirmed the absence of
an EMT phenotype in the ESRP1 knockdown cells. Together, these
data suggest that the induction of EMT by ESRP1 is contextual and
may require the presence of appropriate background conditions.
ESRPs (ESRP1 and ESRP2) are major regulators of the EMT-spli-
cing program [17–19]. Our analysis of the ESRP1 splicing program
in these knockdown models confirmed that the alternative splicing
patterns of most of the EMT-splicing genes were consistent with
prior publications. The TCGA Splice-Seq in cases with low and high
ESRP1 (n = 100 each) confirmed that some of the ASEs observed in
the knockdown cells were identical to those observed in the human
ER+ breast tumors with low ESRP1 levels, validating the active role
of ESRP1 as a splicing factor in ER+ tumors. However, the lack of
overt EMT at the cellular, functional, or pathway levels suggests the
following: (i) In the absence of the appropriate settings, the ESRP1
splicing program may not be sufficient to cause morphological EMT;
(ii) in contrast to the MDA-MB-231 model, ESRP1 knockdown in
ER+ breast cancer promotes a differentiation effect; and (iii) high
ESRP1 and epithelialness promotes cell growth and invasiveness.
These findings are consistent with the dual role of splicing factors
such as ESRP1 based on the tissue and cancer type [35]. The results
of our study, based on the analysis of human breast tumors, suggest
that ESRP1-driven aggressiveness in ER+ breast cancer is indepen-
dent of EMT. This is consistent with data from Taube et al [36],
who have documented that the core EMT gene signature is not asso-
ciated with prognosis in breast cancer.
Furthermore, we identified a novel role for ESRP1 in ER+ breast
cancer cells that impacts tumor progression through the regulation
of genes involved in fatty acid/lipid metabolism and oxidation–
reduction processes. In particular, knockdown of ESRP1 decreased
the expression of key genes in these metabolic pathways. Dysregula-
tion of cellular metabolism has been included as one of the emerg-
ing hallmarks of cancer [23]. Altered metabolism can play a critical
role in cancer progression. During oncogenesis, the metabolic
programming of cancer is complex and requires multiple networks.
The key element of this process is the switch from oxidative meta-
bolism to glycolytic metabolism and the driving force of cancer
proliferation and survival. In this study, we provide the first experi-
mental evidence regarding the splicing factor ESRP1 contributing to
the dysregulation of cellular metabolism.
Fatty acid synthase (FASN) and stearoyl-CoA desaturase 1
(SCD1) are key proteins involved in the endogenous synthesis of
fatty acids and function as important cofactors in various biological
processes. Overexpression of FASN in breast cancer has been associ-
ated with significantly shorter disease-free periods and overall
survival [37–40]. Furthermore, FASN inhibition decreased cell
proliferation and cell viability by promoting apoptosis in hormone-
dependent breast cancer cells [41,42]. In addition, SCD1 catalyzes
Table 2. Alternative splicing events of the genes using HTA validation in ER+ ESRP1 low and high states.
Gene symbol
2C3 versus
2-control
9C2 versus
9-control
Exon locationa GRCh37
2C3 versus
2-control
9C2 versus
9-control
Gene level ASEs
FASN Down Down Chr17:80,055,997–80,056,106 Inc Inc
SCD Down Down Chr10;102,106,772–102,107,288 Inc Inc
PHGDH Down Down Chr1:120,202,421–120,202,536 Inc Inc
CD44 Down Down Multiple exon locations Skip Skip
CTNND1 (p120) NS NS Multiple exon locations Inc Inc
FGFR1 NS NS Multiple exon locations Skip No
FGFR2 Up NS Chr10:123,298,106–123,239,535 Inc No event
aSee Appendix Figs S5 and S6 for Alternative Splicing Events (ASEs) details specific to each gene.
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the conversion of saturated fatty acids into monounsaturated fatty
acids. The increased expression of SCD1 plays a crucial role in medi-
ating glucose versus fatty acid metabolism in the development and
progression of obesity [43]. High SCD1 expression is also associated
with shorter survival in ER+ and HER2+ breast cancer, but not in
ER breast cancers [44]. We further confirmed the significant
decrease in FASN and SCD1 protein expression in tamoxifen-resis-
tant ESRP1 knockdown cells rather than fulvestrant-resistant ESRP1
knockdown cells.
We also verified a decrease in phosphoglycerate dehydrogenase
(PHGDH) protein levels in both tamoxifen- and fulvestrant-resistant
models. PHGDH catalyzes the first step in the serine biosynthesis
pathway. Suppression of PHGDH in cell lines with elevated PHGDH
expression results in a strong decrease in cell proliferation and a
reduction in serine synthesis [45]. Increased expression of PHGDH
was associated with breast cancer subtypes, and ectopic expression
of PHGDH in mammary epithelial cells disrupted acinar morphogen-
esis and induced other phenotypic alterations that may predispose
cells to transformation [46]. Decreased expression impaired prolifer-
ation in amplified cell lines. Indeed, Samanta et al [47] reported that
PHGDH knockdown sensitized both ER+ and ER breast cancer
lines to chemotherapy, resulting in increased mitochondrial reactive
oxygen species (ROS) and apoptosis and loss of chemotherapy-
induced breast cancer stem cells (BCSC) enrichment. They
suggested a role for PHGDH in the formation of secondary (recur-
rent or metastatic) tumors, with potential implications for therapeu-
tic targeting of advanced cancers.
ESRP1 knockdown did not significantly alter the glycolysis rate
(ECAR) in either the tamoxifen-resistant or fulvestrant-resistant
models. However, ESRP1 knockdown significantly increased the
basal respiration and spare respiration capacity, particularly in the
tamoxifen-resistant cells. These promising results warrant further
investigation into the complex nature of ESRP1 knockdown in
metabolic pathways and oxidative phosphorylation in tamoxifen
resistance.
We next validated the changes in metabolic genes that were
observed in the RNA-Seq data at both the mRNA (probed-based
method HTA analysis) and protein levels (Western blot analysis) in
response to ESRP1 knockdown, particularly in the tamoxifen-resis-
tant cells. Some of the variability between the RNA-Seq and HTA
analysis may be due to the differences between the two platforms.
The depth of the RNA-Seq (30 million) may not have been enough
to obtain the same results. Indeed, Nazarov et al [48] reported that
the stochastic variability was higher for the sequencing data than
for microarray data due to the lack of reads for the short and low-
abundance genes. This usually reduces the number of differentially
expressed genes and genes with predictive potential for RNA-Seq
compared to microarray data. HTA 2.0 is a probe-based technology
(10 probes per exon and 4 probes per exon-exon splice junction)
and is independent of the depth bias of RNA-Seq.
In conclusion, this study documents novel roles of ESRP1 in
modifying the behavior of ER+ cells. Although we could confirm its
role in the alternative splicing of EMT-related genes, this did not
result in mesenchymal transformation. Knockdown was associated
with epithelial differentiation and decreased growth by alternative
mechanisms, such as changes in fatty acid and lipid metabolism.
These data could form the basis of new avenues for the control of
recurrence/resistance to therapies in ER+ breast cancer.
Materials and Methods
Analysis of publicly available databases
The prognostic value of ESRP1 and ESRP2 was evaluated using
BreastMark, a tool for examining putative gene prognostic markers
in breast cancer [21]. Its algorithm integrates the gene expression
and survival data from 26 datasets from 12 different microarray
platforms corresponding to approximately 17,000 genes in up to
4,738 samples. The software allows different survival end points to
be analyzed separately. Median expression was used to dichotomize
the data, allowing stratification into high and low groups within
each of the 26 individual datasets. The interface is available on a
publicly accessible web server (BreastMark: Breast Cancer Survival
Analysis Tool [http://glados.ucd.ie/BreastMark/index.html]). The
software uses CGI to link the web server with the R/perl-based algo-
rithm. All calculations are carried out in real time.
Analysis of the Cancer Genome Atlas (TCGA)
Patients with breast cancer were categorized based on their ER
status (n = 924; 656 ERpositive). The clinical information for each
patient was also obtained. The normalized expression of ESRP1 and
ESRP2 (Level 3 data) was analyzed in 924 breast cancer patients
enrolled in The Cancer Genome Atlas (TCGA) database Breast Inva-
sive Carcinoma (BRCA) (https://portal.gdc.cancer.gov/projects/
TCGA-BRCA) study with subtype classification. To model survival,
gene expression at or below median was considered low and above
median was considered high. Overall survival was calculated from
the date of initial diagnosis to disease-specific deaths (patients
whose vital status is termed dead) and months to last follow-up (pa-
tients who are alive). The “survival” package in R (R Foundation for
Statistical Computing) was used for statistical analyses (log rank
test) and to generate Kaplan–Meier curves.
Oncotype DX samples
All protocols were reviewed and approved by the Institutional
Review Board (IRB) of Indiana University. Samples and clinical
records were anonymized prior to access by the authors and linked
with a numerical identifier. The requirement for informed consent
was waived by the IRB. Fifty-nine archival formalin-fixed, paraffin-
embedded (FFPE) tumor blocks were obtained from patients with
ER-positive node-negative breast carcinomas at the Indiana Univer-
sity Simon Cancer Center based on their Oncotype DX RS (19 LS, 20
IS, and 20 HS). Demographic and clinical characteristics of the
patients were acquired from medical charts as described previously
[15].
Breast cancer cell lines
MCF-7-AZ control (endocrine therapy-sensitive), MCF-7-LCC2
(LCC2; tamoxifen-resistant), and MCF-7-LCC9 (LCC9; fulvestrant
(ICI 182,780) and tamoxifen cross-resistant) cell lines were kind
gifts from Dr. R. Clarke (Georgetown University Medical School,
Washington DC) [49,50]. MCF-7 and T-47D cell lines were
purchased from American Type Culture Collection (ATCC, Manas-
sas, VA). Cell lines were carefully maintained in a humidified tissue
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culture incubator at 37°C in a 5% CO2:95% air atmosphere, and
stocks of the earliest passage cells were stored. The cell lines were
grown in phenol red-free DMEM containing 5% charcoal-stripped
fetal calf serum (CCS) and 100 mg/ml penicillin at least 4 days
before the experiments were performed.
RNA isolation and sample quality assessment
Total RNA was extracted from 10-lm-thick sections of archival
paraffin blocks using the RecoverAllTMTotal Nucleic Acid Isolation
Kit (Thermo Fisher Scientific, Wilmington, DE) as described previ-
ously [15]. For breast cancer cell lines, the RNeasy isolation kit was
used according to the manufacturer’s instructions (Qiagen, German-
town, MD). RNA was treated with Turbo DNase (Thermo Fisher
Scientific, Wilmington, DE). The quality of RNA was assessed using
the Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scien-
tific) and the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA).
Quantitative reverse transcription–polymerase chain reaction
(RT–qPCR) of breast cancer cell lines and FFPE samples
Total RNA was reverse-transcribed using the High Capacity cDNA
Reverse Transcription kit (Thermo Fisher Scientific) according the
manufacturer’s instructions. The mRNA levels of ESRP1
(Hs00936420_m1) were analyzed by real-time RT–qPCR using
TaqMan gene expression assays on an ABI Prism 7900 platform
according to the manufacturer’s instructions (Applied Biosystems/
Thermo Fisher Scientific). Actin (ACTB; Hs00357333_g1) and GUSB
(Hs99999908_m1) were used as endogenous controls for normaliza-
tion purposes. All RT–qPCR mixtures from tumor blocks and breast
cancer cell lines were performed in duplicate and triplicate, respec-
tively. For breast cancer cell lines, all experiments were the average
of three independent sets. The relative quantification of the gene
expression changes was analyzed according to the DDCt method
using the Applied Biosystems DataAssistTM Software v3.0. All
graphs were generated using GraphPad Prism 5 software. The error
bars were calculated and represented in terms of the mean  SD.
ESRP1 knockdown in endocrine-resistant cell lines
To stably knockdown ESRP1 expression in the LCC2, LCC9, and T-
47D cells, we performed lentiviral delivery of Mission TRC human
shRNA constructs (pLKO.1 shRNA) according to the manufacturer’s
instructions (Sigma, St. Louis, MO). The following shRNA-Mission
plasmids were used: pLKO.1 control vector (SHC001) and shRNA
ESRP1 (TRCN0000149820, TRCN0000146588). Briefly, 1 × 106 HEK
293 cells were transfected with 2.6 lg each of shRNA- ESRP1 and
control shRNA plasmids and 10 ll packaging mix (Sigma, St. Luis,
MO) using 16 ll FuGENE HD transfection reagent (Roche, Indi-
anapolis, IN). After 48-h incubation, the medium containing the
newly formed viral particles was collected, filtered with millex-HV
0.45-lm filters (Millipore, Burlington, MA), and added to 1.6 ×104
LCC2, LCC9 or T-47D cells together with 8 lg/ml polybrene solution
(Sigma). After 24 h of infection, the cells were washed with PBS
and MEM containing 2 lg/ml puromycin (Invitrogen). Infected cells
were selected in Puromycin media and further passaged in culture
to obtain stable clones that represent ESRP1 knockdown cells.
Overexpression of ESRP1 in MCF-7 breast cancer cell line was
performed using GenScript’s GenEZTMORF ESRP1 construct (ESRP1;
NM_017697). GenScript’s GenEZTMORF ESRP1 was cloned into the
mammalian expression cloning vector pcDNA3.1+/C-(K)-DYK using
CloneEZTMcloning technology according to the manufacturer’s
instructions (GenScript Piscataway, NJ). Stable cells with the control
vector (pcDNA3.1+/C-(K)-DYK vector only) or vector with ESRP1
construct were generated in MCF-7 cells. Knockdown or overexpres-
sion of ESRP1 expression was verified using RT–qPCR and Western
blot assays as described in the Materials and Methods.
Anchorage-independent growth assay
Anchorage-independent growth was determined using the soft agar
colony formation (CytoSelectTM Cell Transformation Assay; Cell
Biolabs Inc., San Diego, CA) according to the manufacturer’s instruc-
tions. Briefly, cells were incubated 8 days in semisolid agar media
before being solubilized, lysed, and detected by the CyQuantR GR
Dye in a fluorescence plate reader under charcoal-stripped media
(CSM) or in response to E2 (1010 M, b-estradiol) or 10% fetal
bovine serum (FBS).
Crystal violet assay
Human breast cancer cells (1 × 103 cells/ml) in DMEM containing
5% charcoal-stripped media were plated in 24-well tissue culture
plates. On day 1 after plating and every 3 days thereafter, cells were
treated with E2 alone (1010 M, Sigma, St. Louis, MO), TAM alone
(4-hydroxytamoxifen; 106 M, Sigma, St. Louis, MO), or in combi-
nation with E2 and TAM. The LCC9 set was also tested for ICI alone
(ICI 182,780-fulvestrant, 109 M, and in combination with E2 and
ICI). On day 6, the media were aspirated, and the cells were stained
with crystal violet (0.2% crystal violet staining solution in buffered
formalin pH = 7.0). Cells were permeabilized using citrate buffer,
and absorbance was read at 560 nm on a plate reader.
Morphology assessment
Cells were grown in 8-well slide chambers (MatTek) in CSS media
for 4 days. The slides were then fixed in 60% ethanol and stained
with H&E stains. The slides were examined under an Olympus BX41
microscope, and images were obtained using a DP-72 camera and
CellSensTMsoftware at 40× magnification.
Orthotopic xenograft models
Six- to eight-week-old female athymic nude mice (Harlan Sprague
Dawley, Indianapolis, IN) were acclimatized for 3–7 days. All
animals were housed in an SPF (specific pathogen-free) facility at
Indiana University. A controlled-release E2 pellet (0.72 mg E2,
60-day formulation; Innovative Research of America, Sarasota,
FL) was injected subcutaneously (s.c.) via a sterile 14-gauge
trocar 24 h before tumor implantation. Five million cells for both
control cells (2-control and 9-control) and ESRP1 knockdown
cells (2C3 and 9C2) were implanted into mammary fat pads.
Tumors were measured weekly using calipers for external
measurements. Tumor volume was calculated as L × W2/2,
where L is length and W is width. All animal experiments were
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performed under a protocol approved by the Indiana University
Institutional Animal Care and Use Committee (IU IACUC). The
investigators were blinded to group allocation during data collec-
tion and analysis.
RNA sequencing with rRNA-depletion TruSeq RNA sample prep
kit, library construction, cluster generation, and HiSeq 2500
Paired-end RNA sequencing (RNA-Seq) was performed using the
Illumina HiSeq 2500 platform by SeqWright Genomic Services
(Houston, TX) according to the manufacturer’s instructions (Illu-
mina, San Diego, CA). Briefly, the first step involved library prepa-
ration using the TruSeq Stranded Total RNA kit. Ribosomal RNAs
(rRNAs) were depleted from total RNA using Ribo-Zero Kits. After
purification and RNA fragmentation, cleaved RNA fragments were
copied into first strand cDNA using reverse transcriptase and
random primers, followed by second-strand cDNA synthesis using
DNA Polymerase I and RNase H. A single “A” base was added to
cDNA fragments with subsequent ligation of the adapter. The prod-
ucts were purified and enriched to create the final cDNA library.
Using the TruSeq Paired-End (PE) Cluster kit, library samples were
amplified to create clonal clusters, and RNA deep sequencing
(TruSeq SBS kit-200 cycles) was performed on the HiSeq 2500 with
the RNA isolated from each sample as described above.
Quality control of protocols and analysis tools using TruSeq RNA
sequencing (Illumina-Hi Seq Platform)
The quality control analysis of the sample library and quantification
of the DNA library templates were validated according to the
manufacturer’s instructions. Briefly, the quality control of the
library sample was checked for the size, purity, and concentration
using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA). In addition, quantitative standards such as RNA spike-
ins were used to calibrate quantification, sensitivity, coverage, and
linearity. Sequencing was performed using total RNAs to a depth of
30 million reads.
Computational methods for RNA-Seq data analysis
Data from total RNA-Seq were processed as described below. Raw
FASTQ sequences were generated and demultiplexed using the Illu-
mina CASAVA pipeline. The FastQC (http://www.bioinformatics.bab
raham.ac.uk/projects/fastqc) and FASTX toolkits (http://hannonlab.c
shl.edu/fastx_toolkit) were used for a quality check to ensure that the
FASTQ reads were in the entirely normal range and to preprocess the
reads prior to mapping. Briefly, the FASTX clipper tool was employed
to remove the Illumina 3 prime adaptor sequences. The postclipped
reads were mapped to the human genome (hg19), and the RNA-Seq-
based gene expression levels (FPKM; fragments per kilobase of exon
per million fragments mapped) were subsequently calculated using
the TopHat/Cufflinks [51,52] framework to increase the mapping
coverage and to generate the SAM/BAM files.
Identifying differential AS events
Differential alternative splicing events between the knockdown and
control cell lines (2C3 versus 2-control and 9C2 versus 9-control)
were identified using MATS.3.0.8 [28–30,53]. Differential splicing
events (defined as P < 0.05 and Δw < 5%) were identified between
the control and knockdown sets.
Identifying ESRP motifs
The splicing map of ESRPs is largely dependent on their binding to
the proximal regions of the target exons, viz upstream, downstream,
or exonic. The position weight matrices (PWM) of the ESRP binding
motifs enriched in the 250 nt upstream, 250 nt downstream, and
exonic regions of ESRP-regulated exons were obtained from
Warzecha et al and Dittmar et al [17–19,31]. These motifs were then
screened in the upstream, downstream, and exonic regions of dif-
ferentially present exons in the control versus knockdown cell lines
using FIMO, a motif prediction tool available in the MEME suite [53].
The motifs identified at P < 0.001 were considered to be significant.
Human Transcriptome Array 2.0 assay and validation
The RNAs from the control and knockdown cells were sent to the
Applied Biosystems/Thermo Fisher Scientific Service laboratory
(Santa Clara, CA). The Ambion Whole-Transcript (WT) Expression
Kit and the GeneChip WT Terminal Labeling and Controls Reagent
Kits were used to prepare the samples. GeneChip Human Transcrip-
tome Array 2.0 was performed according to Applied Biosystems/
Thermo Fisher Scientific’s instructions. Probe cell intensity (CEL)
data generated from the Human Transcriptome Arrays were analyzed
in Transcriptome Analysis Console (TAC) Software to obtain a list of
the differentially expressed genes and alternative splicing events.
TAC software also provided the visualization of genes, exons, junc-
tions, and transcript isoforms. TAC Software was downloaded free
from the Applied Biosystems/Thermo Fisher Scientific website. To
ensure uniform coverage of the transcriptome, the GeneChip Human
Transcriptome Array 2.0 was designed with approximately ten probes
per exon and four probes per exon-exon splice junction. The probes
are all arranged into probe sets that translate and summarize the data
into gene-level, exon-level, and splice-junction probe sets.
TCGA SpliceSeq validation using BRCA dataset
We validated our predictions using the whole exome sequencing
data of breast cancer patients deposited in The Cancer Genome Atlas
Breast Invasive Carcinoma (TCGA-BRCA). We identified 100 Lumi-
nal A samples with extremely low levels of ESRP1 (ESRP1low) and
100 Luminal B samples with high levels of ESRP1 (ESRP1high). The
splicing pattern in these cases was analyzed in TCGA SpliceSeq
using BRCA dataset (http://projects.insilico.us.com/TCGASplice
Seq/). This resource is designed for the investigation of cross-tumor
and tumor-normal alterations in mRNA splicing patterns of TCGA-
BRCA RNA-Seq data [32].
DAVID functional analysis
The functional enrichment analyses were performed using the
DAVID functional annotation tool (http://david.abcc.ncifcrf.gov/).
We identified differentially expressed genes in HTA between the
LCC2 (2-control versus 2C3) and LCC9 (9-control versus 9C2) cells
(FDR < 0.1) and looked for enrichment in the following annotation
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categories: cellular components (GOTERM_CC_FAT), molecular
functions (GOTERM_MF_FAT) or biological processes (GOTERM_
BP_FAT). The clusters are ordered by group enrichment score.
Significant annotation groups were determined by group enrichment
scores ≤ 0.05 (equivalent to 1.3 in minus log scale).
Agilent Seahorse XFp cell energy phenotype assays
The Seahorse XFp Cell Energy Phenotype Test kit is an assay that
simultaneously measures the two major energy-producing pathways
in live cells, mitochondrial respiration, and glycolysis, allowing the
rapid determination of energy phenotypes of cells and investigation
of metabolic switching. Based on the results of the Seahorse XFp
Cell Energy Phenotype Assay, either the Agilent Seahorse XF Cell
Mito Stress test and/or Agilent Seahorse XF Glycolysis Stress are
sequentially performed. The XF Cell Mito Stress test determines
mitochondrial function by directly measuring the oxygen consump-
tion rate (OCR) of cells. The Agilent Seahorse XF Glycolysis Stress
test directly measures the acidification rate and reports this as
ECAR. All OCR and ECAR assays were performed according to the
instructions of Agilent Technologies (Santa Clara, CA). The results
presented are the combination of three independent assays, and
two-way ANOVA analyses were performed using GraphPad soft-
ware (P < 0.05, statistically significant).
Western blot analysis
The protein lysates were prepared, and equal amounts of protein
were subjected to SDS–PAGE and Western blot analysis as described
previously [54]. The Bio-Rad DC-Protein assay kit (Bio-Rad, Hercules,
CA) was used to determine protein concentrations. Blots were incu-
bated with antibodies against CDH1, VIM, SLUG, SNAIL, SNAIL2,
CLAUDIN 1, ZEB1, and ZEB2 (Cell Signaling Technology, Danvers,
MA), FASN (BD Biosciences, San Jose, CA), SCD1 (Alpha Diagnostic
International Inc., San Antonio, TX), and PHGDH (Epigentek, Farm-
ingdale, NY). Antibodies against GAPDH were used as the loading
control (GeneTex, Inc., Irvine, CA). Protein bands were visualized by
SuperSignalTMWest Pico PLUS Chemiluminescent Substrate kit (Amer-
sham, Piscataway, NJ) and Amersham Imager 600 GE Healthcare Life
Sciences (GE Healthcare Bio-Sciences, Pittsburgh, PA). The data are
representative of three individual assay sets.
Statistical analysis
In vitro experiments
Two-way ANOVA tests were used for statistical analysis by
GraphPad Prism 5.0 and Microsoft Excel. All results are representa-
tive of three independent biological replicates and expressed as
mean values SD. In all cases, differences were considered to be
statistically significant at P < 0.05.
Kaplan–Meier curves
BreastMark: Breast Cancer Survival Analysis Tool uses the software
CGI (the web server with the R/perl-based algorithm) to calculate
the P-values for the endpoint “overall survival” using log rank test.
TCGA-BRCA Kaplan–Meier curves: A log rank test was used to
calculate P-values for the endpoint “overall survival” using the
“survival” package in R (R Foundation for Statistical Computing).
Cell cycle analysis
Cell cycle distribution was measured in LCC9 and LCC2 cells trans-
duced with ESRP1 shRNA or nontargeting control shRNA. Cells
were harvested at 24 and 48 h after transfection, suspended in PBS,
and fixed in 70% ethanol. Then, the DNA content was evaluated
after propidium iodide staining. Fluorescence-activated cell-sorting
analysis was carried out using a FACScan flow cytometer (Beckton
Dickinson) and CellQuest software.
Apoptosis assay
The PE Annexin V Apoptosis Detection Kit I (BD Biosciences) was
used with flow cytometry according to the manufacturer’s instruc-
tions. Briefly, ESRP1 shRNA and control shRNA cells (5 × 105 cells/
ml) were harvested, washed in PBS, and pelleted by centrifugation.
The cells were suspended in 1× binding buffer, and then, 5 ll
Annexin V fluorescein isothiocyanate was added. After 15 min,
10 ll propidium iodide was added, and the suspension was incu-
bated in the dark at room temperature for 15 min. Binding buffer
(1×; 400 ll) was added to the suspension and gently vortexed. The
cells were analyzed using a FACScan flow cytometer. The numbers
show the percentages of cells in each quadrant (LL—lower left:
intact cells; LR—lower right: early apoptotic cells; UL—upper left:
necrotic cells; and UR—upper right: late apoptotic or necrotic cells).
Invasion assay
The Boyden in vitro invasion assay was performed as described
previously [55]. Briefly, cells were plated in phenol red free MEM
with 5% charcoal-stripped fetal calf serum for 48 h and switched to
1% serum media for 24 h. The cells were transferred to the upper
chamber of the phenol red free Matrigel-coated transwell plates and
allowed to migrate toward 1% FBS, 10% FBS or E2 (17 beta-estra-
diol; 1010 M) in the lower chamber for 72 h. The cell invasion was
evaluated after DiffQuick staining by counting the cells in four
randomly chosen fields of filters. The results are representative of
the three individual experiments performed in triplicate.
Quantitative reverse transcription–polymerase chain reaction
(RT–qPCR) of CD44 splice variants
Total RNAs were reverse-transcribed using the High Capacity
cDNA Reverse Transcription kit (Thermo Fisher Scientific, Wilm-
ington, DE) according to the manufacturer’s instructions. The
mRNA levels of CD44-all transcript (HS99999195_m1), CD44s
(Hs01081473_m1), and CD44v2-v10 (Hs01075866_m1) were
chosen based on the study by Olsson et al [25] and analyzed by
real-time RT–qPCR using TaqMan gene expression assays on an
ABI Prism 7900 platform according to the manufacturer’s instruc-
tions (Applied Biosystems/Thermo Fisher Scientific). Actin
(ACTB; Hs00357333_g1) was used as an endogenous control for
normalization purposes. All RT–qPCR mixtures from the indicated
breast cancer cell lines were performed in triplicate (*see Materi-
als and Methods for statistical analysis). For the breast cancer
cell lines, all the experiments were the average of three indepen-
dent sets. The relative quantification of the gene expression
changes was analyzed according to the DDCt method using the
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Applied Biosystems DataAssistTM Software v3.0. All graphs were
generated using GraphPad Prism 5 software (two-way ANOVA). The
error bars were calculated and represented in terms of mean  SD.
Glucose uptake and L-lactate levels
The glucose uptake assay was performed using the Glucose Uptake
Assay Kit (Abcam, #ab136955), and the lactate production assay
was performed using the L-Lactate Assay Kit (Abcam, #ab65331)
according to the manufacturer’s protocol. The results were normal-
ized by the protein amounts in each assay.
Data availability
The RNA-Seq data (.bam files) for LCC2 (2-control and ESRP1
knockdown-2C3 cell lines) and LCC9 (9-control and ESRP1 knock-
down-9C2 cell lines) sets were deposited at GEO under accession
GSE125355 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE125355).
Expanded View for this article is available online.
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